The round was led by 5AM Ventures with participation from existing investors Telegraph Hill Partners (THP), founder Ron Seubert and other investors. In conjunction with the funding, Joe Victor (Venture Partner at 5AM Ventures and former CEO of DVS Sciences and Applied Precision) will join the company as President and CEO and continue as a board member. Brian Daniels, MD, Venture Partner at 5AM Ventures will join RareCyte as a board member.
Current CEO Ron Seubert will transition to CTO.
The company will use the funds to advance its commercial sales efforts and build companion diagnostics (CDx) programs with strategic partners as well as to expand its regulatory infrastructure and research and development efforts.
RareCyte provides an integrated rare cell platform, based on the AccuCyte® and CyteFinder® product lines, adopted by academic medical institutions and biopharma companies to advance both pre-clinical research and clinical applications. Leveraging standard microscope slides as the substrate, the platform fits into clinical lab workflows and enables the high-throughput processing of blood samples from clinical studies of all sizes.
CyteFinder can analyze up to 6 biomarker channels using immunofluorescent staining to facilitate deeper analysis of rare cell phenotypes.
The integrated CytePicker® retrieves single cells of interest, allowing customers to build unique phenotype and genotype datasets at the single cell level to advance their research and clinical programs.
FinSMEs
29/08/2017